Salvage chemotherapy for metastatic breast cancer: Results of a phase II study with bendamustine

Annals of Oncology

Volumn 18, Issue 12, 2007, Pages 1981-1984

  Reichmann, Ursula ^a   Bokemeyer, C ^a,b   Wallwiener, D ^c   Bamberg, M ^a   Huober, J ^c,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Bendamustine; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BENDAMUSTINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEART FAILURE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SALVAGE THERAPY; SKIN DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 37349069341     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm378     Document Type: Article

References (11)

1. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002; 29 (4 Suppl 13): 4-11.
2. Mattias M, Preiss R, Sohr R et al. Pharmacokinetics of bendamustine in patients with malignant tumors. Proc Am Soc Clin Oncol 1995; 14: (Abstr 1476).
3. Ruffert K. Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil. Zentralbl Chir 1998; 123 (Suppl 5): 156-158.
4. von Minckwitz G, Chemozemsky I, Sirakova L et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16(8): 871-877.
5. Jamitzky T, Lange OF. Third line chemotherapy with bendamustine for metastatic breast cancer - a prospective pilot study. 7th EORTC Breast Cancer Working Conference. Eur J Cancer 1996; 32A (Suppl 2): 47 (Abstr PP-7-14).
6. Höffken K, Merkle KH, Schönfelder M et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer. A phase II study. J Cancer Res Clin Oncol 1998, 124: 627-632.
7. Therasse P, Arbuck SG, Eisenhauer AE et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000; 92: 205-216.
8. Brockmann B, Geschke E, Schmidt UM et al, Therapeutic results and toxic side effects of the combination of cytostasan, adriamycin and vincristin as second-line therapy of metastatic breast cancer. Geburtshilfe Frauenheilkd 1991; 51(5): 383-386.
9. Relchmann U, Zeeb C, Huober J et al. Bendamustine is a safe and effectve treatment option for pretreated patients with metastatic breast cancer. Results of phase II study. J Cancer Res Clin Oncol 2002; 128 (Suppl 1): 263.
10. Niemeyer C, Bendall H, Reifert J et al. Mitotic catastrophe induced in cells treated with SDX-105 (Treanda™). Proc Am Assoc Cancer Res 2005; 46: (Abstr 2291).
11. Strumberg D, Harstrick A, Doli K et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7: 415-421.